Literature DB >> 15293988

A nonpeptidic sulfonamide inhibits the p53-mdm2 interaction and activates p53-dependent transcription in mdm2-overexpressing cells.

Peter S Galatin1, Donald J Abraham.   

Abstract

The evaluation of a sulfonamide inhibitor of the p53-mdm2 interaction is presented. The compound was identified using 3D database searching techniques based on a computationally derived pharmacophore model of mdm2 binding. It inhibits the physical interaction of recombinant p53 and mdm2 in vitro and increases p53-dependent transcription in an mdm2-overexpressing cell line. Copyright 2004 American Chemical Society

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15293988     DOI： 10.1021/jm034182u

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


  19 in total

Review 1.  Targeting the p53 pathway.

Authors:  Vita M Golubovskaya; William G Cance
Journal:  Surg Oncol Clin N Am       Date:  2013-07-30       Impact factor: 3.495

Review 2.  A cell-free approach to accelerate the study of protein-protein interactions in vitro.

Authors:  E Sierecki; N Giles; M Polinkovsky; M Moustaqil; K Alexandrov; Y Gambin
Journal:  Interface Focus       Date:  2013-10-06       Impact factor: 3.906

Review 3.  Translational approaches targeting the p53 pathway for anti-cancer therapy.

Authors:  Frank Essmann; Klaus Schulze-Osthoff
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

Review 4.  Targeting the p53 signaling pathway in cancer therapy - the promises, challenges and perils.

Authors:  Alexander H Stegh
Journal:  Expert Opin Ther Targets       Date:  2012-01-12       Impact factor: 6.902

5.  Identification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteins.

Authors:  James D Baleja; Jonathan J Cherry; Zhiguo Liu; Hua Gao; Marc C Nicklaus; Johannes H Voigt; Jason J Chen; Elliot J Androphy
Journal:  Antiviral Res       Date:  2006-04-21       Impact factor: 5.970

Review 6.  Drugging the p53 pathway: understanding the route to clinical efficacy.

Authors:  Kian Hoe Khoo; Khoo Kian Hoe; Chandra S Verma; David P Lane
Journal:  Nat Rev Drug Discov       Date:  2014-03       Impact factor: 84.694

7.  Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction.

Authors:  Shanghai Yu; Dongguang Qin; Sanjeev Shangary; Jianyong Chen; Guoping Wang; Ke Ding; Donna McEachern; Su Qiu; Zaneta Nikolovska-Coleska; Rebecca Miller; Sanmao Kang; Dajun Yang; Shaomeng Wang
Journal:  J Med Chem       Date:  2009-12-24       Impact factor: 7.446

8.  Therapeutic considerations for Mdm2: not just a one trick pony.

Authors:  Jason A Lehman; Jacob A Eitel; Christopher N Batuello; Lindsey D Mayo
Journal:  Expert Opin Drug Discov       Date:  2008-11       Impact factor: 6.098

Review 9.  Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.

Authors:  Sanjeev Shangary; Shaomeng Wang
Journal:  Annu Rev Pharmacol Toxicol       Date:  2009       Impact factor: 13.820

10.  Peptide, Peptidomimetic, and Small-molecule Antagonists of the p53-HDM2 Protein-Protein Interaction.

Authors:  Peter M Fischer
Journal:  Int J Pept Res Ther       Date:  2006-03-15       Impact factor: 1.931
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.